Adjuvant role of SeptiFast to improve the diagnosis of sepsis in a large cohort of hematological patients

R Greco, Maria Chiara Barbanti, N Mancini, L Crucitti, C Oltolini, A Forcina, F Lorentino, L Vago, C Messina, Daniela Clerici, M Morelli, Fabio Giglio, MT Lupo Stanghellini, L Infurnari, MG Carrabba, S Marktel, A Assanelli, Paolo Scarpellini, M Bernardi, J PeccatoriC Corti, M Clementi, F Ciceri

Research output: Contribution to journalArticlepeer-review


Febrile neutropenia and sepsis are common and life-threatening complications in hematological diseases. This study was performed retrospectively in 514 patients treated for febrile neutropenia at our institute, to investigate the clinical usefulness of a molecular tool, LightCycler® SeptiFast test (SF), to promptly recognize pathogens causing sepsis in hematological patients. We collected 1837 blood samples of 514 consecutive hematological patients. The time of processing is short. Overall, 757 microorganisms in 663 episodes were detected by molecular test and standard blood cultures (BC): 73.6% Gram-positive bacteria, 23.9% Gram-negative bacteria, and 2.5% fungal species. This large analysis demonstrated a significant episode-to episode agreement (71.9%) between the two methods, higher in negative samples (89.14%), and a specificity of 75.89%. Clinical variables that gave a statistically significant contribution to their concordance were absolute neutrophil count, ongoing antimicrobial therapy, timing of test execution, and organ localization of infection. The large analysis highlights the potential of molecular-based assays directly performed on blood samples, especially if implementing the detection of antibiotic resistance genes, which was lacking in the used study. © 2017 The Author(s) 2017, under exclusive licence to Macmillan Publishers Limited, part of Springer Nature.
Original languageEnglish
Pages (from-to)410-416
Number of pages7
JournalBone Marrow Transplantation
Issue number4
Publication statusPublished - 2018


Dive into the research topics of 'Adjuvant role of SeptiFast to improve the diagnosis of sepsis in a large cohort of hematological patients'. Together they form a unique fingerprint.

Cite this